Observational studyScientific reports2025
Evaluating reporting trends and adverse effects of cosmetic products in Saudi Arabia based on SFDA cosmovigilance data.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective observational study aimed to assess category-specific side effect reporting trends for cosmetic products in the Saudi Arabian market. A total of 1714 reports were analyzed from the Saudi Food and Drug Authority's (SFDA) Cosmovigilance Database over a four-year period (2020-2023). The analysis showed that 53.32% of reports were submitted by males consumer. Phone-based reporting was the most common method (51.16%), followed by submissions through the official vigilance system (45.80%). Reporting activity increased steadily over the years, reflecting enhanced consumer awareness and engagement. Skincare products were the most frequently implicated category, with sensitivity (12.00%) and redness (4.00%) being the top reported adverse effects. Violations were primarily associated with heavy metals and bacterial contamination. The study emphasizes the vital role of the SFDA's cosmovigilance system in maintaining public health and supports continued efforts to promote safe cosmetic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.